Table of Contents
Chapter 1 Methodology and Scope
1.1 Market Segmentation and Scope
1.1.1 Treatment
1.1.3 Regional Scope
1.1.4 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database:
1.3.2 Gvr’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.6.1.1 Approach 1: Commodity Flow Approach
1.6.2 Volume Price Analysis (Model 2)
1.6.2.1 Approach 2: Volume Price Analysis
1.7 List Of Secondary Sources
1.8 List Of Primary Sources
1.9 List Of Abbreviations
1.10 Objectives
1.10.1 Objective 1
1.10.2 Objective 2
1.10.3 Objective 3
1.10.4 Objective 4
Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Segment Snapshot
2.3 Competitive Analysis Snapshot
Chapter 3 End Stage Renal Disease Market Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.2 Ancillary Market Outlook
3.2 Penetration & Growth Prospect Mapping
3.3 Product Pipeline Analysis
3.4 User Perspective Analysis
3.4.1 Consumer Behavior Analysis
3.4.2 Market Influencer Analysis
3.5 List Of Key End Users
3.6 Regulatory Framework
3.7 Market Dynamics
3.7.1 Market Driver Analysis
3.7.1.1 Growing prevalence of diabetes and hypertension
3.7.1.2 Introduction of technologically advanced products
3.7.1.3 Increasing number of patients suffering from chronic kidney disease
3.7.2 Market Restraints Analysis
3.7.2.1 Risk Of Complications
3.7.2.2 Stringent Regulatory Policies For Dialysis Products
3.8 End Stage Renal Disease: Market Analysis Tools
3.8.1 Industry Analysis – Porter’s
3.8.2 Swot Analysis, By Pest
Chapter 4 End Stage Renal Disease Market: Segment Analysis, By Treatment, 2018 – 2030 (USD Million)
4.1 Definition and Scope
4.2 Treatment Market Share Analysis, 2022 & 2030
4.3 Segment Dashboard
4.4 Global End Stage Renal Disease Market, by Treatment, 2018 to 2030
4.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
4.5.1 Dialysis
4.5.1.1 Dialysis Market, 2018 – 2030 (USD Million)
4.5.2 Transplant
4.5.2.1 Transplant Market, 2018 – 2030 (USD Million)
Chapter 5 End Stage Renal Disease Market: Regional Market Analysis, By Treatment, 2018 – 2030 (USD Million)
5.1. Regional market share analysis, 2022 & 2030
5.2. Regional Marketplace: Key Takeaways
5.3. North America
5.3.6. SWOT Analysis
5.3.2. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
5.3.3. U.S.
5.3.3.1. Country Dynamics
5.3.3.2. Country Variables
5.3.3.3. Competitive Landscape
5.3.3.4. Regulatory/Reimbursement Framework
5.3.3.5. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
5.3.4. Canada
5.3.4.1. Country Dynamics
5.3.4.2. Country Variables
5.3.4.3. Competitive Landscape
5.3.4.4. Regulatory/Reimbursement Framework
5.3.4.5. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
5.4. Europe
5.4.1. SWOT Analysis
5.4.2. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
5.4.3. UK
5.4.3.1. Country Dynamics
5.4.3.2. Country Variables
5.4.3.3. Competitive Landscape
5.4.3.4. Regulatory/Reimbursement Framework
5.4.3.5. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
5.4.4. Germany
5.4.4.1. Country Dynamics
5.4.4.2. Country Variables
5.4.4.3. Competitive Landscape
5.4.4.4. Regulatory/Reimbursement Framework
5.4.4.5. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
5.4.5. France
5.4.5.1. Country Dynamics
5.4.5.2. Country Variables
5.4.5.3. Competitive Landscape
5.4.5.4. Regulatory/Reimbursement Framework
5.4.5.5. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
5.4.6. Italy
5.4.6.1. Country Dynamics
5.4.6.2. Country Variables
5.4.6.3. Competitive Landscape
5.4.6.4. Regulatory/Reimbursement Framework
5.4.6.5. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
5.4.7. Spain
5.4.7.1. Country Dynamics
5.4.7.2. Country Variables
5.4.7.3. Competitive Landscape
5.4.7.4. Regulatory/Reimbursement Framework
5.4.7.5. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
5.4.8. Denmark
5.4.8.1. Country Dynamics
5.4.8.2. Country Variables
5.4.8.3. Competitive Landscape
5.4.8.4. Regulatory/Reimbursement Framework
5.4.8.5. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
5.4.9. Sweden
5.4.9.1. Country Dynamics
5.4.9.2. Country Variables
5.4.9.3. Competitive Landscape
5.4.9.4. Regulatory/Reimbursement Framework
5.4.9.5. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
5.4.10. Norway
5.4.10.1. Country Dynamics
5.4.10.2. Country Variables
5.4.10.3. Competitive Landscape
5.4.10.4. Regulatory/Reimbursement Framework
5.4.10.5. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
5.5. Asia Pacific
5.5.6. SWOT Analysis
5.5.2. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
5.5.3. Japan
5.5.3.1. Country Dynamics
5.5.3.2. Country Variables
5.5.3.3. Competitive Landscape
5.5.3.4. Regulatory/Reimbursement Framework
5.5.3.5. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
5.5.4. China
5.5.4.1. Country Dynamics
5.5.4.2. Country Variables
5.5.4.3. Competitive Landscape
5.5.4.4. Regulatory/Reimbursement Framework
5.5.4.5. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
5.5.5. India
5.5.5.1. Country Dynamics
5.5.5.2. Country Variables
5.5.5.3. Competitive Landscape
5.5.5.4. Regulatory/Reimbursement Framework
5.5.5.5. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
5.5.6. Australia
5.5.6.1. Country Dynamics
5.5.6.2. Country Variables
5.5.6.3. Competitive Landscape
5.5.6.4. Regulatory/Reimbursement Framework
5.5.6.5. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
5.5.7. Thailand
5.5.7.1. Country Dynamics
5.5.7.2. Country Variables
5.5.7.3. Competitive Landscape
5.5.7.4. Regulatory/Reimbursement Framework
5.5.7.5. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
5.5.8. South Korea
5.5.8.1. Country Dynamics
5.5.8.2. Country Variables
5.5.8.3. Competitive Landscape
5.5.8.4. Regulatory/Reimbursement Framework
5.5.8.5. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
5.6. Latin America
5.6.1. SWOT Analysis
5.6.2. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
5.6.3. Brazil
5.6.3.1. Country Dynamics
5.6.3.2. Country Variables
5.6.3.3. Competitive Landscape
5.6.3.4. Regulatory/Reimbursement Framework
5.6.3.5. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
5.6.4. Mexico
5.6.4.1. Country Dynamics
5.6.4.2. Country Variables
5.6.4.3. Competitive Landscape
5.6.4.4. Regulatory/Reimbursement Framework
5.6.4.5. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
5.6.5. Argentina
5.6.5.1. Country Dynamics
5.6.5.2. Country Variables
5.6.5.3. Competitive Landscape
5.6.5.4. Regulatory/Reimbursement Framework
5.6.5.5. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
5.7. MEA
5.7.1. SWOT Analysis
5.7.2. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
5.7.3. South Africa
5.7.3.1. Country Dynamics
5.7.3.2. Country Variables
5.7.3.3. Competitive Landscape
5.7.3.4. Regulatory/Reimbursement Framework
5.7.3.5. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
5.7.4. Saudi Arabia
5.7.4.1. Country Dynamics
5.7.4.2. Country Variables
5.7.4.3. Competitive Landscape
5.7.4.4. Regulatory/Reimbursement Framework
5.7.4.5. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
5.7.5. UAE
5.7.5.1. Country Dynamics
5.7.5.2. Country Variables
5.7.5.3. Competitive Landscape
5.7.5.4. Regulatory/Reimbursement Framework
5.7.5.5. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
5.7.6. Kuwait
5.7.6.1. Country Dynamics
5.7.6.2. Country Variables
5.7.6.3. Competitive Landscape
5.7.6.4. Regulatory/Reimbursement Framework
5.7.6.5. Market estimates and forecast, 2018 – 2030 (Revenue, USD Million)
Chapter 6 End Stage Renal Disease Market – Competitive Analysis
6.1 Recent Developments & Impact Analysis, By Key Market Participants
6.2 Company Categorization
6.2.1 Innovators
6.2.2 Market Leaders
6.3 Vendor Landscape
6.3.1 Key Customers
6.3.2 Key Company Market Share Analysis, 2021
6.3.3 Major Deals And Strategic Alliances
6.3.3.1 New Product Launch
6.3.3.2 Expansion
6.3.3.3 Acquistion
6.3.3.4 Marketing & Promotions
6.3.4 Market Entry Strategies
6.4 Public Companies
6.4.1 Company Market Position Analysis
6.4.2 Competitive Dashboard Analysis
6.4.2.1 Market Differentiators
6.5 Private Companies
6.5.1 List Of Key Emerging Companies
6.5.3 Regional Network Map
6.5.4 Company Market Position Analysis
6.6 Company Profiles
6.6.1 Medtronic
6.6.1.1 Company Overview
6.6.1.2 Financial Performance
6.6.1.3 Product Benchmarking
6.6.1.4 Strategic Initiatives
6.6.2 Fresenius Medical Care Ag & Co. Kgaa
6.6.2.1 Company Overview
6.6.2.2 Financial Performance
6.6.2.3 Product/Service Benchmarking
6.6.2.4 Strategic Initiatives
6.6.3 B. Braun Melsungen Ag
6.6.3.1 Company Overview
6.6.3.2 Financial Performance
6.6.3.3 Product/Service Benchmarking
6.6.4 Baxter International, Inc.
6.6.4.1 Company Overview
6.6.4.2 Financial Performance
6.6.4.3 Product Benchmarking
6.6.4.4 Strategic Initiatives
6.6.5 Asahi Kasei Medical Co., Ltd.
6.6.5.1 Company Overview
6.6.5.2 Financial Performance
6.6.5.3 Product Benchmarking
6.6.5.4 Strategic Initiatives
6.6.6 Cantel Medical
6.6.6.1 Company overview
6.6.6.2 Financial performance
6.6.6.3 Product benchmarking
6.6.6.4 Strategic initiatives
6.6.7 BD
6.6.7.1 Company overview
6.6.7.2 Financial performance
6.6.7.3 Product benchmarking
6.6.7.4 Strategic initiatives
6.6.8 NIKKISO CO., LTD
6.6.8.1 Company overview
6.6.8.2 Financial performance
6.6.8.3 Product benchmarking
6.6.8.4 Strategic initiatives
6.6.9 JMS CO. LTD
6.6.9.1 Company overview
6.6.9.2 Financial performance
6.6.9.3 Product benchmarking
6.6.9.4 Strategic initiatives
Table 1 List of secondary sources
Table 2 List of abbreviation
Table 3 North America end stage renal disease market, by country, 2018 - 2030 (USD Million)
Table 4 North America end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
Table 5 U.S. end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
Table 6 Canada end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
Table 7 Europe end stage renal disease market, by country, 2018 - 2030 (USD Million)
Table 8 Europe end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
Table 9 U.K. end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
Table 10 Germany end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
Table 11 France end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
Table 12 Italy end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
Table 13 Spain end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
Table 14 Denmark end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
Table 15 Norway end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
Table 16 Sweden end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
Table 17 Asia Pacific end stage renal disease market, by country, 2018 - 2030 (USD Million)
Table 18 Asia Pacific end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
Table 19 China end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
Table 20 India end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
Table 21 South Korea end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
Table 22 Australia end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
Table 23 Japan end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
Table 24 Thailand end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
Table 25 Latin America end stage renal disease market, by country, 2018 - 2030 (USD Million)
Table 26 Latin America end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
Table 27 Brazil end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
Table 28 Mexico end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
Table 29 Argentina end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
Table 30 Colombia end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
Table 31 Middle East & Africa end stage renal disease market, by country, 2018 - 2030 (USD Million)
Table 32 Middle East & Africa end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
Table 33 South Africa end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
Table 34 South Arabia end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
Table 35 UAE end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
Table 36 Kuwait end stage renal disease market, by treatment, 2018 - 2030 (USD Million)
